Develops engineered T cell therapies for various diseases.
Jun 2026Revenue $7.11M/yrExpenses $128M/yr
No trendCash runway ≈ 10 months from Jun 2026
Figures by year
When will TScan Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $7.11M and expenses $128M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $10.3M | $146M | −$136M |
| Dec 2024 | $2.82M | $138M | −$135M |
| Dec 2023 | $21.0M | $115M | −$93.5M |
| Dec 2022 | $13.5M | $80.2M | −$66.6M |
| Dec 2021 | $10.1M | $58.8M | −$48.6M |
| Dec 2020 | $1.08M | $27.3M | −$26.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.